{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:14:38Z","timestamp":1789496078147,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":395,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jacc.2023.03.414","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T14:26:57Z","timestamp":1684765617000},"page":"2103-2111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["The Inflation Reduction Act and Out-of-Pocket Drug Costs for Medicare\u00a0Beneficiaries With Cardiovascular Disease"],"prefix":"10.1016","volume":"81","author":[{"given":"Dhruv S.","family":"Kazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette","family":"DeJong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi K.","family":"Wadhera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Wen","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.jacc.2023.03.414_bib1","doi-asserted-by":"crossref","first-page":"6998","DOI":"10.1073\/pnas.1920391117","article-title":"US life expectancy stalls due to cardiovascular disease, not drug deaths","volume":"117","author":"Mehta","year":"2020","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"10.1016\/j.jacc.2023.03.414_bib2","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke statistics-2022 update: a report from the American Heart Association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jacc.2023.03.414_bib3","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamacardio.2017.3451","article-title":"Association of prior authorization and out-of-pocket costs with patient access to PCSK9 inhibitor therapy","volume":"2","author":"Navar","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"4","key":"10.1016\/j.jacc.2023.03.414_bib4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1377\/hlthaff.2021.01742","article-title":"Many Medicare beneficiaries do not fill high-price specialty drug prescriptions","volume":"41","author":"Dusetzina","year":"2022","journal-title":"Health Aff Proj Hope"},{"key":"10.1016\/j.jacc.2023.03.414_bib6","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jacc.2023.02.002","article-title":"Out-of-pocket drug costs for Medicare beneficiaries with cardiovascular risk factors\/conditions under the Inflation Reduction Act","volume":"81","author":"Narasimmaraj","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.03.414_bib7","first-page":"1267","article-title":"Cost-effectiveness and affordability of novel cardiovascular therapies: what physicians need to know","volume":"107","author":"Ferro","year":"2021","journal-title":"Heart Br Card Soc"},{"key":"10.1016\/j.jacc.2023.03.414_bib8","doi-asserted-by":"crossref","first-page":"E151","DOI":"10.5888\/pcd17.200244","article-title":"Cost-related nonadherence and mortality in patients with chronic disease: a multiyear investigation, national health interview survey, 2000-2014","volume":"17","author":"Van Alsten","year":"2020","journal-title":"Prev Chronic Dis"},{"key":"10.1016\/j.jacc.2023.03.414_bib9","series-title":"The Health Costs of Cost-Sharing","author":"Chandra","year":"2021"},{"issue":"16","key":"10.1016\/j.jacc.2023.03.414_bib10","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJMp2211223","article-title":"Impending relief for Medicare beneficiaries\u2014the Inflation Reduction Act","volume":"387","author":"Dusetzina","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jacc.2023.03.414_bib11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jamacardio.2022.5033","article-title":"Estimation of out-of-pocket costs for guideline-directed medical therapy for heart failure under Medicare Part D and the Inflation Reduction Act","volume":"8","author":"Johnson","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"15","key":"10.1016\/j.jacc.2023.03.414_bib14","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jacc.2023.03.414_bib15","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jamainternmed.2020.2922","article-title":"Out-of-pocket costs for novel guideline-directed diabetes therapies under Medicare Part D","volume":"180","author":"DeJong","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"8","key":"10.1016\/j.jacc.2023.03.414_bib16","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1001\/jamacardio.2019.2223","article-title":"Assessment of national coverage and out-of-pocket costs for sacubitril\/valsartan under Medicare Part D","volume":"4","author":"DeJong","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"10","key":"10.1016\/j.jacc.2023.03.414_bib17","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1001\/jamacardio.2017.3051","article-title":"Nationwide coverage and cost-sharing for PCSK9 inhibitors among Medicare Part D plans","volume":"2","author":"Kazi","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"4","key":"10.1016\/j.jacc.2023.03.414_bib18","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/jamainternmed.2016.9386","article-title":"Medicare Part D plans\u2019 coverage and cost-sharing for acute rescue and preventive inhalers for chronic obstructive pulmonary disease","volume":"177","author":"Tseng","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"10","key":"10.1016\/j.jacc.2023.03.414_bib19","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","article-title":"STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"4","author":"von Elm","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.jacc.2023.03.414_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2021.106715","article-title":"Prevalence and predictors of cost-related medication nonadherence in individuals with cardiovascular disease: results from the Behavioral Risk Factor Surveillance System (BRFSS) survey","volume":"153","author":"Kherallah","year":"2021","journal-title":"Prev Med"},{"issue":"1","key":"10.1016\/j.jacc.2023.03.414_bib21","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/jep.13745","article-title":"Cost-related medication nonadherence among Medicare beneficiaries with cardiovascular disease risk factors: the role of comprehension of the Medicare programme and its prescription drug benefits","volume":"29","author":"Park","year":"2023","journal-title":"J\u00a0Eval Clin Pract"},{"issue":"22","key":"10.1016\/j.jacc.2023.03.414_bib22","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1056\/NEJMsa1107913","article-title":"Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) Trial. Full coverage for preventive medications after myocardial infarction","volume":"365","author":"Choudhry","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.jacc.2023.03.414_bib23","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.jacc.2023.03.414_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.14501","article-title":"Cost-effectiveness of dapagliflozin for the treatment of heart failure with reduced ejection fraction","volume":"4","author":"Isaza","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2023.03.414_bib25","author":"Department of Health and Human Services"},{"issue":"1","key":"10.1016\/j.jacc.2023.03.414_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.5218","article-title":"Simulated Medicare drug price negotiation under the Inflation Reduction Act of 2022","volume":"4","author":"Rome","year":"2023","journal-title":"JAMA Health Forum"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109723052270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109723052270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:56:25Z","timestamp":1760018185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109723052270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":23,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0735109723052270"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2023.03.414","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Inflation Reduction Act and Out-of-Pocket Drug Costs for Medicare\u00a0Beneficiaries With Cardiovascular Disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2023.03.414","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}